Market Place
Sourcing Support
Chemomab`s CM-101 Shows Activity in Primary Sclerosing Cholangitis
19 Nov 2024 //
GLOBENEWSWIRE
Chemomab Reports Q3 2024 Results & Corporate Update
14 Nov 2024 //
GLOBENEWSWIRE
Chemomab Therapeutics to Report Q3 2024 Results & Update
30 Oct 2024 //
GLOBENEWSWIRE
Chemomab Announces Presentation Of Ph 2 Results At AASLD Meeting
15 Oct 2024 //
GLOBENEWSWIRE
Chemomab Therapeutics to Present at Oct 2024 Investor Conferences
01 Oct 2024 //
GLOBENEWSWIRE
Chemomab Therapeutics to Present at September 2024 Investor Conferences
28 Aug 2024 //
GLOBENEWSWIRE
Chemomab Reports Q2 2024 Results And Provides Corporate Update
21 Aug 2024 //
GLOBENEWSWIRE
Chemomab To Report Q2 2024 Results And Provide Business Update
12 Aug 2024 //
GLOBENEWSWIRE
Chemomab Therapeutics Announces Closing of $10 Million Private Placement
30 Jul 2024 //
GLOBENEWSWIRE
Chemomab Regains Nasdaq Compliance With Minimum Bid Price Requirement
26 Jul 2024 //
GLOBENEWSWIRE
Chemomab Reports Positive Phase 2 Results For CM-101 In PSC
25 Jul 2024 //
GLOBENEWSWIRE
Chemomab Therapeutics Announces $10 Million Private Placement
25 Jul 2024 //
GLOBENEWSWIRE
Chemomab trumpets liver disease win, but investors retreat
25 Jul 2024 //
FIERCE BIOTECH
Chemomab Announces New Publications On CM-101 For Sclerosing Cholangitis
18 Jun 2024 //
GLOBENEWSWIRE
Chemomab Presents Data On CM-101 For PSC At EASL 2024 And GRC
06 Jun 2024 //
GLOBENEWSWIRE
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
17 May 2024 //
GLOBENEWSWIRE
Chemomab Q1 2024 Financials And Corporate Update
09 May 2024 //
GLOBENEWSWIRE
Chemomab Gets 180 Days For Nasdaq Minimum Bid Compliance
08 May 2024 //
GLOBENEWSWIRE
Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference
02 May 2024 //
GLOBENEWSWIRE
Chemomab to Report Q1 2024 Results, Business Update
24 Apr 2024 //
GLOBENEWSWIRE
Chemomab: New Data Links CCL24 To Systemic Sclerosis Severity
18 Apr 2024 //
GLOBENEWSWIRE
Chemomab Announces Year End and Fourth Quarter 2023 Financial Results
07 Mar 2024 //
PR NEWSWIRE
Chemomab Awarded New Patents for CM-101
20 Feb 2024 //
PR NEWSWIRE
Chemomab to Report Fourth Quarter and Full Year 2023 Financial Results
14 Feb 2024 //
PR NEWSWIRE
Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Trial
03 Jan 2024 //
PR NEWSWIRE
Chemomab Presentation at ACR Provides Further Support for Key Role of Its CCL24
16 Nov 2023 //
PRESS RELEASE
Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101
15 Nov 2023 //
PRESS RELEASE
Chemomab Presents Data for CM-101`s Anti-Fibrotic/Anti-Inflammatory Activity
13 Nov 2023 //
PRESS RELEASE
Chemomab Therapeutics Announces Third Quarter 2023 Financial Results
09 Nov 2023 //
PR NEWSWIRE
Chemomab Discloses Receipt of Nasdaq Notice Regarding Bid Price Requirement
06 Nov 2023 //
PRESS RELEASE
Chemomab Therapeutics to Report Third Quarter 2023 Financial Results
30 Oct 2023 //
PR NEWSWIRE
Chemomab Therapeutics Announces Second Quarter 2023 Financial Results
14 Aug 2023 //
PR NEWSWIRE
Chemomab Therapeutics Presents Data Reinforcing the Clinical Potential of CM-101
26 Jun 2023 //
PR NEWSWIRE
Chemomab Reports +ve Data from Secondary Analysis of Phase 2a Liver
21 Jun 2023 //
PR NEWSWIRE
Chemomab changes CEOs; Ex-FDA vaccine official lends help to Mesoblast
09 Jun 2023 //
ENDPTS
Chemomab Therapeutics to Provide a Corporate Update on April 17, 2023
29 Mar 2023 //
PR NEWSWIRE
Chemomab to Discuss Fourth Quarter and Full-Year 2022 Financial Results
17 Mar 2023 //
PR NEWSWIRE
Chemomab Announces FDA Clearance of Investigational NDA for PII Trial of CM-101
21 Feb 2023 //
PRESS RELEASE
Chemomab Announces Appointment of Matthew Frankel, MD as Chief Medical Officer
14 Nov 2022 //
PRNEWSWIRE
Chemomab Presents Clinical Data from Investigator-Initiated Study CM-101
09 Nov 2022 //
PRNEWSWIRE
Chemomab Therapeutics to Report Second Quarter 2022 Financial Results
01 Aug 2022 //
PRNEWSWIRE
Chemomab Awarded New U.S. Patent for CM-101
28 Jun 2022 //
PRNEWSWIRE
Chemomab Presents Data Further Supporting MOA and Potential Efficacy of CM-101
27 Jun 2022 //
PRNEWSWIRE
Data Supporting Role of Chemomab`s Novel Therapeutic Target CCL24
02 Jun 2022 //
PRNEWSWIRE
Chemomab Tx to Present at the 32nd Annual Oppenheimer Healthcare Conference
10 Mar 2022 //
PRNEWSWIRE
Chemomab Therapeutics to Present at Aegis Virtual Conference
10 Feb 2022 //
PRNEWSWIRE
Chemomab gain 8% on collaboration with Leeds University in systemic sclerosis
27 Sep 2021 //
SEEKINGALPHA
Chemomab Announces Appointment of Dale Pfost as Chief Executive Officer
02 Sep 2021 //
PRNEWSWIRE
Chemomab and AGC Biologics Partner to Manufacture CM-101 for Phase II/III
24 Jun 2021 //
CONTRACTPHARMA
Chemomab Announces Poster Presentation at the International Liver Congress 2021
10 Jun 2021 //
PRNEWSWIRE
Chemomab Announces Enrollment of First Patient in Phase 2a Study of CM-101 NASH
26 Apr 2021 //
PRNEWSWIRE
Chemomab Announces Enrollment of First Patient in Phase 2a Study of CM-101
26 Apr 2021 //
PRNEWSWIRE
Chemomab Announces First Patient Enrolled in Phase IIa Study of CM-101
02 Feb 2021 //
BIOSPACE
Chemomab Announces Positive Phase Ib Results of its SPARK study testing CM-101
05 Jan 2021 //
PRNEWSWIRE
Chemomab Announces Positive Phase Ib Results of its SPARK study CM-101
05 Jan 2021 //
PRNEWSWIRE
Anchiano and Chemomab Announce Entry Into Merger Agreement
15 Dec 2020 //
GLOBENEWSWIRE
Chemomab Announces Late-Breaking Presentation of CM-101 Evidence
19 Oct 2020 //
PRNEWSWIRE
Chemomab Receives European Orphan Drug Designation for CM-101
26 Aug 2020 //
PRNEWSWIRE
Chemomab gets UK & Israel regulatory approvals to begin phase II trial CM-101
24 Jul 2020 //
PHARMABIZ
